THE DEAL, AT A GLANCE
1/4 reviewedVinci Pharmaceuticals
Vinci Pharmaceuticals
Vinci develops EPIPLANT, needle-free drug delivery for treating retinal diseases inside the eye.
Vinci Pharmaceuticals raised $8M Series A, announced 2026-10-0801What it doesVinci develops EPIPLANT, needle-free drug delivery for treating retinal diseases inside the eye.Source-grounded · automated review · Explore ↗
Checked 2026-10-08 · Review due 2026-10-15
Read supporting source ↗Our proprietary solution is EPIPLANT™,…
02Who is involvedBacked by Silas CapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedVinci Pharmaceuticals raised $8M Series A, announced 2026-10-08From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersVinci Pharmaceuticals raised Series A capital in a thinly disclosed pharmaceutical financing.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Vinci Pharmaceuticals · Financing Record
Explore source-linked visual explanations for Vinci Pharmaceuticals. Unsupported claims are withheld while source review continues.
Record 13683 · Recorded date: 2026-10-08
Explore company records →